VSPharmTech
June 25, 2026
Theater 1
Type: Company Presentation
Focus Area:
Oncology
VSPharmTech (VSPT) is a clinical-stage biotech company dedicated to its core mission: "Discovering the Better for a Paradigm Shift in Cancer Treatment." The company specializes in developing innovative therapeutics that address the clinical limitations of conventional cancer treatments while prioritizing patient-centric solutions to ensure safety and quality of life for patients.
The pipeline is built upon two pillars with a singular goal: maximizing anti-tumor impact by striking at the core of cancer survival and blocking the route of cancer invasion. The portfolio includes VS-101, an apoptosis enhancer in Phase 2 clinical trials for head and neck cancer, glioblastoma, and breast cancer; VS-P301, a HRD inducer for ovarian cancer; and VS-501, a first-in-class anti-metastatic agent targeting for solid tumors. Through this pipeline, VSPT is redefining the oncology landscape—ensuring that "better" treatment means not only survival but a healthier life during and after recovery.
Company HQ City:
232 Gongneung-ro
Company HQ State:
Seoul
Company HQ Country:
Korea, Republic of
Year Founded:
2018
Lead Product in Development:
Apoptosis enhancer VS-101
CEO
ShinYoung Park
Development Phase of Lead Product
Phase II
When you expect your next catalyst update?
2026
What is your next catalyst (value inflection) update?
Securing the interim data of VS-101 for Phase 2 clinical trials in head and neck cancer
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}